5MJC RCCU 3: Sunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCCSunitinib Continuous 37.5 mg/Day Dosing in Cytokine-Refractory Metastatic RCC 5MJC RCCU 2: Everolimus in Patients with Cytokine-Pretreated mRCCEverolimus in Patients with Cytokine-Pretreated mRCC 5MJC RCCU 1: Presurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell CarcinomaPresurgical Feasibility of Bevacizumab for Nephrectomy-Eligible, Treatment-Naïve Patients with Metastatic Renal Cell Carcinoma Subscription | Sign up to receive your complimentary copy of Breast Cancer Update Think TankIf you would like to to receive immediate notification and a link to download our Breast Cancer Update Think Tank program when it’s available online, or to receive the program by mail in hard copy with audio CDs†, please take a moment to fill out the brief form below and indicate your preference of email, hard copy or both. †Hard copy by mail currently available to practicing US clinicians only. * This field is required. Subscription | Sign up to receive your complimentary copy of Renal Cell Think TankIf you would like to to receive immediate notification and a link to download our Renal Cell Think Tank program when it’s available online, or to receive the program by mail in hard copy with audio CDs†, please take a moment to fill out the brief form below and indicate your preference of email, hard copy or both. †Hard copy by mail currently available to practicing US clinicians only. * This field is required. |